Clinical Trial Update: Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating regorafenib after progression on atezolizumab plus bevacizumab in advanced hepatocellular carcinoma is ongoing with unknown st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• Regorafenib (regorafenib)

Snippet

Sponsor: CHA University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN